Novartis Pledges New Integrity Efforts In Letter To FDA Detailing Manipulation Of Data On New Drug

Novartis and the Food and Drug Administration disclosed in August they had identified data manipulation in testing of a gene-therapy treatment, but the FDA is probing why Novartis didn’t disclose the manipulation when it first became aware of it earlier. The company says its probe was hindered by two employees, who were later fired. Also, Novartis announced that it is expanding its recall of a heartburn drug to the U.S.

from Kaiser Health News https://ift.tt/2kZKmcq